Aprobarbital
From Wikipedia, the free encyclopedia
|
Aprobarbital
|
|
| Systematic (IUPAC) name | |
| 5-propan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione | |
| Identifiers | |
| CAS number | |
| ATC code | N05 |
| PubChem | |
| Chemical data | |
| Formula | C10H14N2O3 |
| Mol. mass | 210.23 g/mol |
| Synonyms | Aprobarbital, Oramon, Allylpropymal, Alurate, 5-Isopropyl-5-allylbarbituric acid |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Aprobarbital (Oramon) is a barbiturate derivative invented in the 1920s by Ernst Preiswerk. It has sedative, hypnotic and anticonvulsant properties, and was used primarily for the treatment of insomnia. [1] Aprobarbital was never as widely used as more common barbiturate derivatives such as phenobarbital and is now rarely prescribed as it has been replaced by newer drugs with a better safety margin.
[edit] References
- ^ Reddemann H, Turk E. Oramon poisoning in infancy and childhood. Observations on 12 aprobarbital poisonings (German). Das Deutsche Gesundheitswesen. 1966 May 12;21(19):878-81.
|
|||||

